What are New Additions in 2023?
1. Detailed industry forecast
2. More information on the company’s key players
3. On-demand customized reports and analyst assistance
4. Recent market developments and future growth prospects
5. Requested customized regional/country reports
What is biosimilar market?
The biosimilar market size reached US$ 15.9 Billion in 2021. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers.
Download Sample PDF at: https://www.alliedmarketresearch.com/request-sample/162
The global biosimilars market was valued at $15.9 billion in 2021, and is projected to reach $143.6 billion by 2031, growing at a CAGR of 24.7% from 2022 to 2031.
- Forecast Growing Region: APAC
- Largest Market: North America
- Projection Time: 2021 – 2031
- Base Year: 2020
Increase in incidences of diabetes and autoimmune diseases drives the growth of the global biosimilars market. Moreover, favorable government policies and new product launches in the biosimilars industry have supplemented the growth yet more. Moreover, several growth prospects in the developed as well as developing economies have been beneficial for the key players in the industry.
Covid-19 scenario-
- The COVID-19 pandemic created difficulties for the pharmaceutical industry to focus on R&D activities including biosimilar development, which impacted the global biosimilars market negatively.
- Moreover, there was a delay in product approvals and product launches, owing to the global health crisis, which further restricted the expansion of the market.
The commercialization of filgrastim biosimilars in the United States have brought the revolutionary changes in development of biosimilars. Pharmaceutical companies interested in investing into biosimilars market are now focusing on the agreement and acquisitions, in order to expand their presence in biosimilars market. Recently, the Pfizer has acquired Hospira, a global leader in biosimilars. This acquisition has strengthen the biosimilar portfolio of Pfizer. Also, it increases the global reach of Hospira through commercial capabilities, scientific expertise of Pfizer. The key companies profiled in the report are Novartis (Sandoz), Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec, Inc., and Genentech (Roche Group).
Ask to Our Industry Expert: https://www.alliedmarketresearch.com/request-for-customization/162?reqfor=covid
Europe garnered the major share in 2021-
Based on region, Europe held the major share in 2021, generating nearly two-fifths of the global biosimilars market. At the same time, the same region would also grow at the fastest CAGR of 25.9% by 2031. This is attributed to rise in the prevalence of cancer and increase in launches of multiple biosimilars in the region.
Key players in the industry-
- Exxon Mobil Corporation
- Haihang Industry Co., Ltd.
- Kent elastomer products
- Kuraray Co.
- Shell,Ltd.
- SIBUR
- Dupont
- The Goodyear Tire & Rubber Company
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry